Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23.122
Filtrar
1.
BMC Gastroenterol ; 24(1): 168, 2024 May 17.
Artigo em Inglês | MEDLINE | ID: mdl-38760713

RESUMO

BACKGROUND: Transcatheter angiography (TA) could help to diagnose and treat refractory nonvariceal upper gastrointestinal bleeding (NVUGIB). Proton pump inhibitors (PPIs) are the key medication for reducing the rebleeding rate and mortality and are usually continued after TA. It is unknown whether high-dose PPIs after TA are more effective than the standard regimen. METHODS: We retrospectively collected data from patients who received TA because of refractory NVUGIB from 2010 to 2020 at West China Hospital. 244 patients were included and divided into two groups based on the first 3 days of PPIs treatment. All baseline characteristics were balanced using the inverse probability of treatment weighting method. The 30-day all-cause mortality, rebleeding rate and other outcomes were compared. The propensity score matching method was also used to verify the results. RESULTS: There were 86 patients in the high-dose group and 158 in the standard group. The average daily doses of PPI were 192.1 ± 17.9 mg and 77.8 ± 32.0 mg, respectively. Cox regression analysis showed no difference in the 30-day all-cause mortality (aHR 1.464, 95% CI 0.829 to 2.584) or rebleeding rate (aHR 1.020, 95% CI 0.693 to 1.501). There were no differences found in red blood cell transfusion, hospital stay length and further interventions, including endoscopy, repeating TA, surgery and ICU admission. The results were consistent in the subgroup analysis of patients with transcatheter arterial embolization. CONCLUSION: In refractory NVUGIB patients who received TA, regardless of whether embolization was performed, high-dose PPI treatment did not provide additional benefits compared with the standard regimen.


Assuntos
Hemorragia Gastrointestinal , Inibidores da Bomba de Prótons , Humanos , Hemorragia Gastrointestinal/terapia , Hemorragia Gastrointestinal/mortalidade , Hemorragia Gastrointestinal/diagnóstico por imagem , Hemorragia Gastrointestinal/etiologia , Masculino , Feminino , Inibidores da Bomba de Prótons/uso terapêutico , Inibidores da Bomba de Prótons/administração & dosagem , Estudos Retrospectivos , Pessoa de Meia-Idade , Idoso , Recidiva , Angiografia/métodos , Resultado do Tratamento , China , Pontuação de Propensão
2.
J Med Case Rep ; 18(1): 253, 2024 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-38764047

RESUMO

BACKGROUND: Splenic artery pseudoaneurysm is a rare complication of recurrent pancreatitis usually presenting as an incidental finding on abdominal computed tomography. CASE PRESENTATION: We present the case of a 66-year-old north African male with a known history of previous pancreatitis who presented with upper gastrointestinal bleeding along with recurrent epigastric pain for 3 days. Investigations did not reveal any particular pancreatitis etiology. Computed tomography of the abdomen with contrast showed splenic artery pseudoaneurysm along with findings suggestive of acute pancreatitis. Upper and lower endoscopies failed to identify gastrointestinal the bleed source. The patient underwent intervention radiology embolization of the aneurysm sac with multiple coils via right retrograde common femoral artery-celiac access. The patient was discharged with a plan for capsule endoscopy in outpatient setting. CONCLUSION: Splenic artery pseudoaneurysm is a life-threatening complication and carries a high mortality rate if left untreated. Prompt identification through various imaging modalities, followed by urgent intervention, is crucial to avoid adverse outcomes.


Assuntos
Falso Aneurisma , Embolização Terapêutica , Artéria Esplênica , Tomografia Computadorizada por Raios X , Humanos , Falso Aneurisma/diagnóstico por imagem , Falso Aneurisma/terapia , Masculino , Artéria Esplênica/diagnóstico por imagem , Idoso , Pancreatite/complicações , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/terapia , Dor Abdominal/etiologia , Resultado do Tratamento
3.
Sci Rep ; 14(1): 10725, 2024 05 10.
Artigo em Inglês | MEDLINE | ID: mdl-38730079

RESUMO

Despite a lack of evidence, patients are often not fed for 48-96 h after upper gastrointestinal bleeding (UGIB); however, many trials have demonstrated the benefits of early nutrition (EN). We conducted a meta-analysis of randomized controlled trials (RTCs) to evaluate the outcomes of EN compared to delayed nutrition (DN) after UGIB. The protocol was registered on PROSPERO (CRD42022372306). PubMed, Embase, CENTRAL, Scopus, and Web of Science were searched on the 27th of April 2024 to identify eligible RCTs. The primary outcomes were early (within 7 days) and late (within 30-42 days) mortality and rebleeding. Pooled risk ratios (RR), mean differences (MD), and corresponding 95% confidence intervals (CI) were calculated using a random-effects model. A total of 10 trials with 1051 patients were included in the analysis. Early mortality was not significantly different between the two groups (RR 1.20, CI 0.85-1.71, I2 = 0%), whereas late mortality was reduced to a clinically relevant extent in the EN group (RR 0.61, CI 0.35-1.06, I2 = 0%). When comparing the two groups, we found no significant difference in terms of early and late rebleeding (RR 1.04, CI 0.66-1.63, I2 = 0% and RR 1.16, CI 0.63-2.13, I2 = 0%, respectively). Our analysis also showed that the length of hospital stay was reduced in the EN group compared to the DN group (MD -1.22 days, CI: -2.43 to -0.01, I2 = 94%). In conclusion, compared with DN, EN (within 24 h) appears to be a safe intervention and could reduce the length of hospital stay without increasing the risk of complications after UGIB.


Assuntos
Hemorragia Gastrointestinal , Ensaios Clínicos Controlados Aleatórios como Assunto , Humanos , Hemorragia Gastrointestinal/mortalidade , Hemorragia Gastrointestinal/etiologia , Tempo de Internação , Resultado do Tratamento
5.
J Med Case Rep ; 18(1): 239, 2024 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-38725071

RESUMO

BACKGROUND: Radiation proctitis (RP) is a significant complication of pelvic radiation. Effective treatments for chronic RP are currently lacking. We report a case where chronic RP was successfully managed by metformin and butyrate (M-B) enema and suppository therapy. CASE PRESENTATION: A 70-year-old Asian male was diagnosed with prostate cancer of bilateral lobes, underwent definitive radiotherapy to the prostate of 76 Gy in 38 fractions and six months of androgen deprivation therapy. Despite a stable PSA nadir of 0.2 ng/mL for 10 months post-radiotherapy, he developed intermittent rectal bleeding, and was diagnosed as chronic RP. Symptoms persisted despite two months of oral mesalamine, mesalamine enema and hydrocortisone enema treatment. Transition to daily 2% metformin and butyrate (M-B) enema for one week led to significant improvement, followed by maintenance therapy with daily 2.0% M-B suppository for three weeks, resulting in continued reduction of rectal bleeding. Endoscopic examination and biopsy demonstrated a good therapeutic effect. CONCLUSIONS: M-B enema and suppository may be an effective treatment for chronic RP.


Assuntos
Enema , Metformina , Proctite , Neoplasias da Próstata , Lesões por Radiação , Humanos , Masculino , Proctite/tratamento farmacológico , Proctite/etiologia , Idoso , Metformina/uso terapêutico , Metformina/administração & dosagem , Neoplasias da Próstata/radioterapia , Neoplasias da Próstata/tratamento farmacológico , Lesões por Radiação/tratamento farmacológico , Doença Crônica , Resultado do Tratamento , Butiratos/uso terapêutico , Hemorragia Gastrointestinal/tratamento farmacológico , Hemorragia Gastrointestinal/terapia , Hemorragia Gastrointestinal/etiologia , Supositórios
7.
World J Gastroenterol ; 30(18): 2482-2484, 2024 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-38764765

RESUMO

The present letter to the editor is related to the study with the title "Automatic detection of small bowel (SB) lesions with different bleeding risk based on deep learning models". Capsule endoscopy (CE) is the main tool to assess SB diseases but it is a time-consuming procedure with a significant error rate. The development of artificial intelligence (AI) in CE could simplify physicians' tasks. The novel deep learning model by Zhang et al seems to be able to identify various SB lesions and their bleeding risk, and it could pave the way to next perspective studies to better enhance the diagnostic support of AI in the detection of different types of SB lesions in clinical practice.


Assuntos
Inteligência Artificial , Endoscopia por Cápsula , Aprendizado Profundo , Hemorragia Gastrointestinal , Intestino Delgado , Humanos , Endoscopia por Cápsula/métodos , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/diagnóstico , Intestino Delgado/patologia , Intestino Delgado/diagnóstico por imagem , Medição de Risco/métodos
8.
Rev Gastroenterol Peru ; 44(1): 67-70, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38734914

RESUMO

Acute gastric variceal bleeding is a life-threatening condition that could be effectively treated with endoscopic cyanoacrylate injection diluted with lipiodol. The mixture acts as a tissue adhesive that polymerizes when in contact with blood in a gastric varix. This work reports a patient that presented to the emergency department with upper gastrointestinal bleeding due to acute variceal bleeding, who developed systemic embolization following cyanoacrylate injection therapy. This complication culminated in cerebral, splenic and renal infarctions with a fatal outcome. Systemic embolization is a very rare, but the most severe complication associated with endoscopic cyanoacrylate injection and should be considered in patients undergoing this treatment.


Assuntos
Cianoacrilatos , Varizes Esofágicas e Gástricas , Hemorragia Gastrointestinal , Adesivos Teciduais , Humanos , Cianoacrilatos/uso terapêutico , Cianoacrilatos/administração & dosagem , Cianoacrilatos/efeitos adversos , Embolia/etiologia , Embolia/terapia , Embolização Terapêutica/métodos , Varizes Esofágicas e Gástricas/terapia , Varizes Esofágicas e Gástricas/etiologia , Evolução Fatal , Hemorragia Gastrointestinal/terapia , Hemorragia Gastrointestinal/etiologia , Adesivos Teciduais/uso terapêutico , Adesivos Teciduais/administração & dosagem
9.
Ann Med ; 56(1): 2349180, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38699840

RESUMO

BACKGROUND: Sarcopenia is a common complication of liver cirrhosis and can be used for predicting dismal prognostic outcomes. This study aimed to evaluate the role of sarcopenia in rebleeding and mortality of liver cirrhosis patients after endoscopic therapy. METHODS: The liver cirrhosis patients who received endoscopic treatment were enrolled. Propensity score matching (PSM) was used to overcome selection bias. Two-year rebleeding episodes and mortality after endoscopic therapy were recorded. RESULTS: A total of 109 (32.4%) sarcopenia patients were reported. Before PSM, the frequency of rebleeding was significantly higher in the sarcopenia group relative to the non-sarcopenia group (41.3% vs. 15.9%, p < 0.001). Moreover, the multivariable analysis revealed that sarcopenia (p < 0.001, HR:2.596, 95% CI 1.591-4.237) was independently associated with a 2-year rebleeding episode. After PSM, the sarcopenia group exhibited an increased rebleeding rate as compared with non-sarcopenia group (44.4% vs. 15.3%, p < 0.001). According to multivariable analysis, sarcopenia (p < 0.001, HR:3.490, 95% CI 1.756-6.938) was identified as a significant predictor for 2-year rebleeding. CONCLUSION: Sarcopenia was significantly associated with a high 2-year rebleeding rate in liver cirrhosis patients after endoscopic treatment. Therefore, the precise evaluation of a patient's nutritional status, including sarcopenia becomes mandatory before endoscopic treatment.


Assuntos
Varizes Esofágicas e Gástricas , Hemorragia Gastrointestinal , Cirrose Hepática , Pontuação de Propensão , Recidiva , Sarcopenia , Humanos , Sarcopenia/etiologia , Sarcopenia/epidemiologia , Sarcopenia/complicações , Masculino , Feminino , Hemorragia Gastrointestinal/etiologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Varizes Esofágicas e Gástricas/etiologia , Cirrose Hepática/complicações , Idoso , Adulto , Fatores de Risco , Prognóstico
12.
Adv Rheumatol ; 64(1): 37, 2024 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-38702826

RESUMO

OBJECTIVE: It is well-established that patients with a history of gout are more susceptible to experiencing gastrointestinal bleeding. Gout flare during active gastrointestinal bleeding poses a significant challenge due to the gastrointestinal side effects of anti-inflammatory therapy. This study sought to investigate the risk factors associated with gout flares during episodes of gastrointestinal bleeding. METHODS: We conducted a retrospective observational study involving 94 patients who experienced active gastrointestinal bleeding and had a history of gout. This study was conducted at Jinhua Municipal Central Hospital from January 2019 to October 2022. We collected and recorded demographic information and clinical characteristics. RESULTS: Among the gout flare patients, hyperuricemia and intravenous fat emulsion therapy were more prevalent compared to those who remained stable (81.6% vs. 57.8% and 46.9% vs. 24.4%, p < 0.05). Multivariate logistic regression analysis revealed that both hyperuricemia (odds ratio 2.741, 95% CI 1.014-7.413, p = 0.047) and intravenous fat emulsion therapy (odds ratio 2.645, 95% CI 1.046-6.686, p = 0.040) were independent predictors of gout flares. Furthermore, gout attacks occurred sooner in patients receiving intravenous fat emulsion therapy compared to those not receiving it (median: 4 days (interquartile range: 2) vs. median: 5 days (interquartile range: 2.25), p = 0.049). CONCLUSION: Our study revealed a high incidence of gout flares during episodes of active gastrointestinal bleeding, with patients undergoing intravenous fat emulsion therapy and those with hyperuricemia being at increased risk.


Assuntos
Emulsões Gordurosas Intravenosas , Hemorragia Gastrointestinal , Gota , Hiperuricemia , Humanos , Hiperuricemia/complicações , Gota/complicações , Gota/tratamento farmacológico , Masculino , Fatores de Risco , Feminino , Hemorragia Gastrointestinal/etiologia , Estudos de Casos e Controles , Estudos Retrospectivos , Pessoa de Meia-Idade , Emulsões Gordurosas Intravenosas/efeitos adversos , Emulsões Gordurosas Intravenosas/uso terapêutico , Emulsões Gordurosas Intravenosas/administração & dosagem , Exacerbação dos Sintomas , Idoso
13.
Rev Col Bras Cir ; 51: e20243600, 2024.
Artigo em Inglês, Português | MEDLINE | ID: mdl-38716913

RESUMO

INTRODUCTION: In 2020, the world suffered a major impact from the COVID-19 pandemic, especially due to the high transmissibility of the virus. It is a disease that predominates with respiratory manifestations, but there is involvement of the gastrointestinal tract, causing symptoms ranging from mild to more severe. Highlighting gastrointestinal bleeding, it is a symptom resulting from the involvement of the SARS-CoV-2 virus described by several reports and case series. METHODS: through an integrative literature review, of a qualitative nature, works that corresponded to the eligibility criteria were selected, totaling 16 articles included in this review. RESULTS: of the patients who manifested gastrointestinal symptoms associated with the disease, common comorbidities and clinical manifestations were identified, in addition to therapies used to treat the infection, which were predisposing factors for the development of gastrointestinal bleeding. CONCLUSION: The presence of gastrointestinal bleeding in patients with COVID-19 is established in the literature, since the pathophysiological mechanisms of the disease directly affect the GIT. Early recognition of symptoms and suspicion of gastrointestinal involvement allows better management of patients and complications.


Assuntos
COVID-19 , Hemorragia Gastrointestinal , Humanos , COVID-19/complicações , Hemorragia Gastrointestinal/etiologia , SARS-CoV-2 , Fatores de Risco
16.
Clin Imaging ; 110: 110168, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38703476

RESUMO

BACKGROUND & AIM: Esophageal varices (EV) screening guidelines have evolved with improved risk stratification to avoid unnecessary esophagogastroduodenoscopy (EGD) in individuals with low bleeding risks. However, uncertainties persist in the recommendations for certain patient groups, particularly those with hepatocellular carcinoma (HCC) and/or receiving non-selective beta-blockers (NSBB) without prior endoscopy. This study assessed the efficacy of imaging in ruling out EVs and their high-risk features associated with bleeding in patients with cirrhosis and with HCC. We also evaluated the impact of NSBB on the detection of these characteristics. METHODS: A total of 119 patients undergoing EGD with CT and/or MRI within 90 days of the procedure were included. 87 patients had HCC. A new imaging grading system was developed utilizing the size of EVs and the extent of their protrusion into the esophagus lumen. The negative predictive value (NPV) of EVimaging(-) versus EVimaging (+) (grades 1-3) in ruling out the presence of EV and/or high-risk features by EGD was calculated. The predictive performance of imaging was determined by logistic regression. RESULTS: The NPV of imaging for detecting EV and high-risk features was 81 % and 92 %, respectively. Among HCC patients, the NPV for EV and high-risk features was 80 % and 64 %, respectively. Being on NSBB didn't statistically impact the imaging detection of EV. Imaging was a better predictor of high-risk EGD findings than Child-Turcotte-Pugh scores. CONCLUSIONS: Our results suggest that imaging can effectively rule out the presence of EV and high-risk features during EGD, even in patients with HCC and/or receiving NSBB.


Assuntos
Varizes Esofágicas e Gástricas , Hemorragia Gastrointestinal , Cirrose Hepática , Imageamento por Ressonância Magnética , Tomografia Computadorizada por Raios X , Humanos , Varizes Esofágicas e Gástricas/diagnóstico por imagem , Varizes Esofágicas e Gástricas/etiologia , Masculino , Feminino , Pessoa de Meia-Idade , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Tomografia Computadorizada por Raios X/métodos , Hemorragia Gastrointestinal/diagnóstico por imagem , Hemorragia Gastrointestinal/etiologia , Idoso , Carcinoma Hepatocelular/diagnóstico por imagem , Carcinoma Hepatocelular/complicações , Estudos Retrospectivos , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/complicações , Endoscopia do Sistema Digestório/métodos , Medição de Risco , Adulto , Valor Preditivo dos Testes
17.
Med Sci Monit ; 30: e943126, 2024 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-38704632

RESUMO

BACKGROUND Severe anemia caused by hemorrhoidal hematochezia is typically treated preoperatively with reference to severe anemia treatment strategies from other etiologies. This retrospective cohort study included 128 patients with hemorrhoidal severe anemia admitted to 3 hospitals from September 1, 2018, to August 1, 2023, and aimed to evaluate preoperative blood transfusion requirements. MATERIAL AND METHODS Of 5120 patients with hemorrhoids, 128 (2.25%; male/female: 72/56) experienced hemorrhoidal severe anemia, transfusion, and Milligan-Morgan surgery. Patients were categorized into 2 groups based on their preoperative hemoglobin (PHB) levels after transfusion: PHB ≥70 g/L as the liberal-transfusion group (LG), and PHB <70 as the restrictive-threshold group (RG). The general condition, bleeding duration, hemoglobin level on admission, transfusion volume, length of stay, immune transfusion reaction, surgical duration, and hospitalization cost were compared between the 2 groups. RESULTS Patients with severe anemia (age: 41.07±14.76) tended to be younger than those with common hemorrhoids (age: 49.431±15.59 years). The LG had a significantly higher transfusion volume (4.77±2.22 units), frequency of immune transfusion reactions (1.22±0.58), and hospitalization costs (16.69±3.31 thousand yuan) than the RG, which had a transfusion volume of 3.77±2.09 units, frequency of immune transfusion reactions of 0.44±0.51, and hospitalization costs of 15.00±3.06 thousand yuan. Surgical duration in the LG (25.69±14.71 min) was significantly lower than that of the RG (35.24±18.72 min). CONCLUSIONS Patients with hemorrhoids with severe anemia might require a lower preoperative transfusion threshold than the currently recognized threshold, with an undifferentiated treatment effect and additional benefits.


Assuntos
Anemia , Transfusão de Sangue , Hemorroidas , Cuidados Pré-Operatórios , Humanos , Masculino , Feminino , Estudos Retrospectivos , Anemia/terapia , Anemia/etiologia , Transfusão de Sangue/métodos , Pessoa de Meia-Idade , Adulto , Hemorroidas/cirurgia , Hemorroidas/complicações , Cuidados Pré-Operatórios/métodos , Hemoglobinas/análise , Hemoglobinas/metabolismo , Tempo de Internação , Hemorragia Gastrointestinal/cirurgia , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/terapia , Idoso
19.
Best Pract Res Clin Gastroenterol ; 69: 101912, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38749579

RESUMO

Endoscopic resection techniques have evolved over time, allowing effective and safe resection of the majority of pre-malignant and early cancerous lesions in the gastrointestinal tract. Bleeding is one of the most commonly encountered complications during endoscopic resection, which can interfere with the procedure and result in serious adverse events. Intraprocedural bleeding is relatively common during endoscopic resection and, in most cases, is a mild and self-limiting event. However, it can interfere with the completion of the resection and may result in negative patient-related outcomes in severe cases, including the need for hospitalization and blood transfusion as well as the requirement for radiological or surgical interventions. Appropriate management of intraprocedural bleeding can improve the safety and efficacy of endoscopic resection, and it can be readily achieved with the use of several endoscopic hemostatic tools. In this review, we discuss the recent advances in the approach to intraprocedural bleeding complicating endoscopic resection, with a focus on the various endoscopic hemostatic tools available to manage such events safely and effectively.


Assuntos
Hemorragia Gastrointestinal , Hemostase Endoscópica , Humanos , Hemostase Endoscópica/métodos , Hemostase Endoscópica/efeitos adversos , Hemostase Endoscópica/instrumentação , Hemorragia Gastrointestinal/cirurgia , Hemorragia Gastrointestinal/etiologia , Resultado do Tratamento , Endoscopia Gastrointestinal/efeitos adversos , Endoscopia Gastrointestinal/métodos , Perda Sanguínea Cirúrgica/prevenção & controle , Hemostáticos/administração & dosagem , Hemostáticos/uso terapêutico
20.
Best Pract Res Clin Gastroenterol ; 69: 101907, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38749583

RESUMO

A significant problem encountered in the resection of large, complex colonic polyps is delayed bleeding. This can occur up to two weeks after the procedure and is a significant source of comorbidity. Untreated it can prove life threatening. It is therefore a priority of modern endoscopy to develop and employ techniques to minimaize this. In this article we will review and discuss the evidence base and controversies in this field, with cold EMR technique, Post-EMR clip closure, and topical haemostatic agents.


Assuntos
Pólipos do Colo , Colonoscopia , Hemorragia Pós-Operatória , Humanos , Pólipos do Colo/cirurgia , Hemorragia Pós-Operatória/prevenção & controle , Hemorragia Pós-Operatória/etiologia , Colonoscopia/efeitos adversos , Ressecção Endoscópica de Mucosa/efeitos adversos , Fatores de Tempo , Hemostáticos/uso terapêutico , Hemostáticos/administração & dosagem , Resultado do Tratamento , Hemorragia Gastrointestinal/prevenção & controle , Hemorragia Gastrointestinal/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA